Related Experiment Video
Updated: Jul 16, 2026
09:26
A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
Published on: March 23, 2016
Pharmacological neuroprotection for glaucoma.
Glyn Chidlow1, John P M Wood, Robert J Casson
1Ophthalmic Research Laboratories, South Australian Institute of Ophthalmology, Hanson Institute, Adelaide, South Australia, Australia. glyn.chidlow@imvs.sa.gov.au
Drugs
|March 28, 2007
Summary
Pharmacological neuroprotection offers a new strategy for glaucoma, a neurodegenerative disease. By targeting retinal cells and the optic nerve, this approach aims to preserve vision beyond just lowering eye pressure.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Background:
- Glaucoma is a neurodegenerative disease causing optic nerve damage and retinal ganglion cell (RGC) death.
- Elevated intraocular pressure is a primary risk factor, but RGC loss persists even with controlled pressure.
- New therapeutic strategies are essential for glaucoma management.
Purpose of the Study:
- To explore pharmacological neuroprotection as a novel treatment strategy for glaucoma.
- To identify and evaluate potential molecular targets for neuroprotective drugs in glaucoma.
- To assess the potential of pharmacological interventions to preserve RGC survival.
Main Methods:
- Utilized chronic glaucoma animal models to understand disease pathology.
- Investigated various molecular targets including glutamate receptors, autoimmune factors, and oxidative stress.
- Examined the role of neurotrophins, nitric oxide, ion channels, heat shock proteins, and apoptotic pathways.
Main Results:
- Animal models have identified multiple pathological processes in glaucoma.
- Several molecular targets have been manipulated with varying success in preclinical studies.
- Emerging data suggests promising avenues for pharmacological intervention.
Conclusions:
- Pharmacological neuroprotection represents a significant advancement in glaucoma treatment research.
- Targeting specific pathways offers a potential to halt or slow RGC degeneration.
- Further research is poised to yield effective neuroprotective therapies for glaucoma.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...